With Kite in the bag, Gilead boosts oncology chief Riva to the head table

gilead4
Alessandro Riva’s new job comes with a seat on Gilead’s top leadership team, and puts him in charge of all of Gilead’s oncology programs, including cell therapy R&D.

What comes after a successful M&A hunt? A promotion for the lead deal scout. Weeks after sewing up a $11.9 billion deal for Kite Pharma and its cell therapy engine, Gilead Sciences said it's promoting Alessandro Riva to head up its burgeoning oncology business as an executive vice president.

Riva’s new job comes with a seat on Gilead’s top leadership team, and it puts him in charge of all of Gilead’s oncology programs, including cell therapy R&D. That means he’ll be presiding over Kite's forthcoming CAR-T medication Axi-Cel, now waiting in the wings at the FDA for an approval.

RELATED: Gilead's new deal scout faces tough task as investors clamor for M&A

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Riva joined Gilead in January from Novartis, where he ran the oncology business, which just happens to be Gilead's next big rival. Novartis won FDA approval for its CAR-T therapy Kymriah in August and has since officially launched it with a $475,000 price tag. Kite and Novartis had been neck-and-neck in the race to bring the first CAR-T drug to market.

The Novartis and Kite drugs will be used to treat different groups of patients initially, but the companies are testing beyond those populations and could eventually find themselves competing head to head.

RELATED: Growth-hungry Gilead finally pivots from flagging hep C with $12B Kite buy

For Gilead, the M&A move for Kite gives the company an opportunity to shift away from its troubled hep C business. For many analysts and investors, the decision was long overdue. As the hep C business took a dive in recent years, industry watchers had been clamoring quarter after quarter for the company to buy something. During that time, CEO John Milligan suggested oncology was one area of focus.

In making the buy, Milligan said Gilead shares Kite's belief that "cell therapy will be the cornerstone of treating cancer." Analysts have said Kite's lead drug could generate up to $2 billion in peak sales.

Suggested Articles

Industry watchers have been speculating about just how high Novartis would price gene therapy Zolgensma. And now, they have an answer.

The WHO’s role in part is to provide prescribing guidance without an eye on profits. What happens when that guidance is tainted by private money?

After 19 sales reps left Amgen to help Karyopharm launch a rival multiple myeloma drug, Amgen sued. Now Karyopharm wants the suit thrown out.